Brian Kotzin

Interim Chief Medical Officer & Head of Development at Nektar Therapeutics

Brian Kotzin

Brian Kotzin

Interim Chief Medical Officer & Head of Development at Nektar Therapeutics

Overview
RelSci Relationships

2269

Number of Boards

8

Birthday

1950

Age

71

Relationships
RelSci Relationships are individuals Brian Kotzin likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Rigel Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director, Diabetes Research Program, Director, Center for Interventional Immunology, Member at Benaroya Research Institute at Virginia Mason

Relationship likelihood: Strong

Managing Director at Westlake Village BioPartners

Relationship likelihood: Strong

President & Chief Executive Officer at Nektar Therapeutics

Relationship likelihood: Strong

Senior Vice President & Chief Commercial Officer at Nektar Therapeutics

Relationship likelihood: Strong

President at Benaroya Research Institute at Virginia Mason

Relationship likelihood: Strong

Chief Operating Officer & Executive Director at Benaroya Research Institute at Virginia Mason

Relationship likelihood: Strong

President at Federation of Clinical Immunology Societies, Inc.

Relationship likelihood: Strong

Foundation President at American College of Rheumatology

Relationship likelihood: Strong

Chief Executive Officer at ShangPharma Innovation, Inc.

Relationship likelihood: Strong

Paths to Brian Kotzin
Potential Connections via
Relationship Science
You
Brian Kotzin
Interim Chief Medical Officer & Head of Development at Nektar Therapeutics
Education

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

A leader in the Biomedical Revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.

Career History
Interim Chief Medical Officer & Head of Development
2017 - Current

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Vice President-Global & Clinical Development
2004 - 2015

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Director-Autoimmunity Center of Excellence
Prior

University of Colorado Health is a Front Range health system that delivers the highest quality patient care with the highest quality patient experience. University of Colorado Health combines Memorial Hospital, Poudre Valley Hospital, Medical Center of the Rockies, Colorado Health Medical Group, and University of Colorado Hospital into an organization dedicated to health and providing unmatched patient care in the Rocky Mountain West. UCHealth partners with the University of Colorado School of Medicine and numerous community organizations to provide care.

Boards & Committees
Member, Board of Directors
2020 - Current

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Member, Board of Directors
2019 - Current

Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Member, Board of Directors
2017 - Current

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Director
Current

American College of Rheumatology is an American nonprofit company located in Atlanta, GA. The firm operates as an organization for physicians and health professionals. It was founded by Göran Albert Torstensson Ando.The company says this about itself: The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.

Director
Current

FEDERATION OF CLINICAL IMMUNOLOGY SOCITIES, INC. (FOCIS) PROVIDES A SCIENTIFIC FORUM TO FOSTER THE CROSS-DISCIPLINARY APPROACH TO IMPROVING HUMAN HEALTH THROUGH IMMUNOLOGY.

Member, Scientific Advisory Board
Prior

RESEARCH FOR CAUSES AND CURE OF LUPUS

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Brian Kotzin. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Brian Kotzin's profile does not indicate a business or promotional relationship of any kind between RelSci and Brian Kotzin.